These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: β-2 agonists in sport: are the anti-doping rules meeting the needs of asthmatic athletes?
    Author: Orellana JN, Márquez MD.
    Journal: Br J Sports Med; 2011 Aug; 45(10):809-12. PubMed ID: 19955160.
    Abstract:
    OBJECTIVES: (a) To review the methacholine tests performed in our laboratory up until 2008; (b) to compare them with previously reported data in 2006 and (c) to examine if the anti-doping rules are meeting the needs of asthmatic athletes who really need bronchodilator treatment. METHODS: Between April 2004 and September 2008, 89 high-level athletes were examined in our laboratory in order to obtain an abbreviated therapeutic use exemption for β-2 agonists. Of these, 50 men (23.31 (7.05) years) and 23 women (20.68 (5.94) years) performed a methacholine inhalation test with increasing concentrations of methacholine (0.025, 0.25, 2.5, 5, 10 and 25 mg/ml) until a fall of 20% in forced expiratory volume in 1 s (FEV(1)) was achieved. RESULTS: 31 candidates (42.5%) had a provocative concentration causing a 20% fall in FEV(1) (PC(20)) <2 mg/ml; 12 (16.4%) were between 2 and 4 mg/ml; 8 (11%) between 4.1 and 8 mg/ml and 22 candidates (30.1%) had a PC(20) >8 mg/ml. Seven of the 73 candidates had an obstructive pattern in the spirometry at rest, demonstrated by a FEV(1)% <70% but with a FEV(1) >70% of the reference value. CONCLUSIONS: The anti-doping regulations with respect to β-2 agonists need to be reviewed, and measures should be adopted to include a fall of 70% in FEV(1)% as an obstruction criterion to indicate a bronchodilation test and to extend the criterion for a positive methacholine test to a PC(20) of 8 mg/ml.
    [Abstract] [Full Text] [Related] [New Search]